A candid look at the European drug regulatory network from a key player
This article was originally published in SRA
Executive Summary
In an exclusive interview with Scrip Regulatory Affairs, Jytte Lyngvig, a key player for many years in the European drug regulatory network and until recently head of the Danish Medicines Agency*, talks to Maureen Kenny about the future of the network and Denmark’s role in it, the EMA, transparency, adaptive licensing and the image of the pharmaceutical industry.